Nitrogen

Where Does the Nitrogen Go?

Phenylbutyrate, sodium benzoate and ornithine take different routes to nitrogen disposal. Understanding those routes explains both the appeal of combining them and the limits of the cancer-treatment argument.

Ammonia can be converted into another molecule without its nitrogen leaving the body. It can move from blood into tissue, become part of an amino acid, and later be released again. A lower ammonia measurement therefore tells only part of the story. To understand a disposal strategy, follow the nitrogen to the compound that actually leaves in urine.

Phenylbutyrate (PB), sodium benzoate (SB) and ornithine are often discussed together because all can participate in nitrogen management. Their jobs are different. PB and benzoate provide alternative urinary routes through amino-acid conjugation. Ornithine participates in the body's own urea cycle and can also support ammonia capture into glutamine. The illustration maps these distinct roles.^[1][2][3][4]

Follow the nitrogen to its exit. Gold circles represent nitrogen atoms. The counts describe urinary products; they do not rank treatment effectiveness. CoA activation and intermediate reactions are omitted. View the illustration at full size.

A successful nitrogen-disposal strategy has to connect capture or conversion with excretion. In cancer, it must also improve the balance between tumour survival and effective immune killing.

Phenylbutyrate: exporting glutamine nitrogen

PB first undergoes β-oxidation to form phenylacetate. After activation, phenylacetate conjugates with glutamine to produce phenylacetylglutamine, usually abbreviated PAGN. The kidneys excrete PAGN in urine. Because glutamine contains two nitrogen atoms, each PAGN molecule carries two nitrogen atoms out of the body.^[1]

PB → phenylacetate
Phenylacetate + glutamine → PAGN → urine

Calling PB an “ammonia scavenger” is useful shorthand, but it can obscure the chemistry. PB does not directly bind two free ammonia molecules. It removes nitrogen already incorporated into glutamine. How that changes ammonia depends on the wider metabolic system replenishing and using the glutamine pool.^[1]

The formulation also matters when describing evidence. Sodium phenylbutyrate and glycerol phenylbutyrate both deliver PB, but they are different preparations. Phenylacetate is the downstream metabolite. A study using one should retain that name when its results are reported.

Sodium benzoate: exporting glycine nitrogen

Sodium benzoate supplies benzoate. After conversion to benzoyl-CoA, benzoate conjugates with glycine to form hippurate, also called hippuric acid. Hippurate is then excreted in urine. Glycine contributes one nitrogen atom, so each hippurate molecule removes one nitrogen atom.^[2]

Benzoate + glycine → hippurate → urine

PB and benzoate therefore draw on different amino-acid pools and form different urinary products. Both can provide routes around urea synthesis. Neither makes the need for metabolic processing and renal excretion disappear. The sodium in their names is not the nitrogen-carrying component.^[1][2]

Ornithine: a recycled participant in urea production

In the liver, ornithine enters a cycle through citrulline, argininosuccinate and arginine. The final reaction releases urea and regenerates ornithine, allowing another turn. Urea enters the blood and is excreted by the kidneys. Its two nitrogen atoms enter the cycle through ammonia and aspartate; they are not the nitrogen atoms of the ornithine being recycled.^[3]

This makes “two nitrogens removed per ornithine molecule” the wrong interpretation of the diagram. The count belongs to urea. Ornithine is an intermediate, and supplying more of an intermediate does not guarantee more flow through a pathway. The result depends on functioning enzymes, substrate availability and the physiological setting.

Ornithine can also support a second process: formation of glutamine. Glutamine synthetase joins ammonia nitrogen to glutamate, creating glutamine. Glutamate already contains one nitrogen atom, so this step captures one additional ammonia nitrogen. The resulting glutamine carries two.^[4]

Glutamate (1 N) + ammonia (1 N)
→ glutamine (2 N)

That captures and transports nitrogen, but does not yet remove it from the body. Glutamine can subsequently be broken down and release ammonia. Linking its formation to an excretion route is therefore a meaningful combination hypothesis.

What the two–one–two labels actually mean

Nitrogen export and the role of each intervention

Intervention	Nitrogen source for the product	Urinary product	Nitrogen atoms per product molecule
Phenylbutyrate	Glutamine	Phenylacetylglutamine (PAGN)	2
Sodium benzoate	Glycine	Hippurate	1
Ornithine-supported urea cycle	Ammonia and aspartate	Urea; ornithine is recycled	2

Product stoichiometry describes where nitrogen goes. Actual clearance depends on how much product is formed and excreted.^[1][2][3]

The arithmetic cannot establish that PB is twice as effective as benzoate, or that ornithine matches PB. Those comparisons would require comparable exposures and measured outcomes. Ornithine also brings its own nitrogen into the system when supplemented; nitrogen balance must account for what enters as well as what leaves.

Why combinations can make metabolic sense

PB plus benzoate: another route, with a cost advantage

A randomized crossover study in seven healthy adults compared sodium PB, sodium benzoate and a mixture containing half of each corresponding single-agent dose. The mixture used an SB:PB mass ratio of 1:1.3, approximately equal molar amounts.^[5]

The mixture and full-dose PB produced similar nitrogen excretion through their drug conjugates. The mixture cost less using the study's institutional prices. This was a small metabolic study, not a formal demonstration of clinical equivalence. Total urinary nitrogen and urea production did not differ significantly between treatments. Neither cancer control nor clinical benefit in hyperammonaemic patients was established.^[5]

The result supports investigating whether less PB can be used while retaining a particular nitrogen-disposal effect. It does not establish a cancer regimen, and the financial saving depends on current local prices and formulation.

PB plus ornithine: connecting capture with export

The proposed division of labour is different here. Ornithine can support ammonia incorporation into glutamine; PB provides a route for exporting that glutamine nitrogen as PAGN. Coupling the processes could limit the recycling of captured nitrogen back into ammonia.

This concept has direct experimental support. In bile-duct-ligated rats, an acute study compared native L-ornithine, PB, the combination and saline. The combination improved arterial ammonia and brain-water measurements that the individual agents did not significantly improve under those conditions.^[4]

That is evidence of cooperation in a liver-disease model. It does not demonstrate that the pair treats cancer, or that it will work when the relevant metabolic steps are impaired. Studies of native ornithine, L-ornithine L-aspartate and ornithine phenylacetate also need to remain distinct; their results cannot be substituted for one another.

What changes when the goal is cancer control?

A tumour contains malignant cells, immune cells and supporting tissue with different metabolic needs. Removing a harmful metabolite can improve one population's function while helping another survive. The cancer question is therefore whether nitrogen handling changes the outcome of their interaction.

There is a substantive reason to investigate this. In colorectal-cancer mouse experiments, accumulated ammonia impaired T cells, and ammonia-lowering interventions improved particular tumour outcomes. Glycerol phenylbutyrate reduced MC38 tumour size. Ornithine also reduced growth in selected models; the successful combination with anti-PD-L1 used ornithine. That checkpoint result cannot be attributed to PB or to PB plus ornithine.^[6]

Phenylbutyrate

More than nitrogen disposal

PB has effects beyond its nitrogen-excretion pathway. In liver-cancer models, early 4-PBA exposure promoted stem-cell-associated behaviour through PPARα and Wnt signalling. Timing and tumour context mattered. A metabolic rationale therefore needs direct testing against the tumour response.^[7]

Sodium benzoate

A metabolic effect can stop short of tumour control

In a HeLa xenograft study, benzoate potentiated glycine depletion with SHMT2 suppression but did not significantly reduce tumour growth. In separate noncancer experiments, benzoate increased TGF-β-associated regulatory T cells. The immune finding raises a concern to test; it does not prove tumour promotion.^[8][9]

Ornithine

The destination of the substrate matters

Favourable colorectal-cancer findings coexist with a breast-cancer mouse model in which oral ornithine impaired T-cell function and abolished anti-PD-1 benefit in a stiff-collagen setting. Ornithine's participation in nitrogen disposal does not make supplementation uniformly helpful.^[10]

Even apparent cancer-cell killing needs an exposure check. Sodium benzoate induced apoptosis in colorectal-cancer cultures at high millimolar concentrations, with toxicity also observed in the normal-cell comparator. Those results establish biological activity under the tested conditions; they do not establish an effective anticancer treatment in humans.^[11]

The most defensible cancer hypothesis is consequently conditional: identify a tumour in which ammonia contributes to immune dysfunction, demonstrate that the intervention lowers ammonia in that tumour, and establish that the resulting immune benefit outweighs any protection or stimulation of malignant cells.

Measure the route and the outcome

A useful experiment needs to connect several observations. Urinary PAGN or hippurate can confirm export through the alternative pathways. Blood and tumour ammonia measurements address different compartments. Glutamine, glycine and ornithine measurements help explain substrate changes. Functional T-cell assays and tumour growth then test whether the biological result is useful.

The combination must be compared with both individual agents. Otherwise, an improvement over one drug can conceal a second drug that contributes nothing—or merely corrects a problem caused by the first.

The illustration is a map of possible nitrogen exits. It explains why PB, benzoate and ornithine can cooperate metabolically, and why they cannot be treated as interchangeable. A cancer-treatment claim requires the next link: showing that the chosen route improves tumour control and the host's ability to sustain it.

This post compares simplified human pathways with selected human and preclinical findings. Nitrogen atom counts are not dose recommendations or rankings of clinical efficacy. The experimental combinations discussed here have not been established as cancer treatments.

Sources and evidence

Mechanism, human nitrogen-disposal measurements and cancer outcomes are identified separately below.

1. DailyMed. Sodium phenylbutyrate prescribing information. Clinical pharmacology.Official drug information: PB metabolism, glutamine conjugation and renal PAGN excretion. ↩
2. DailyMed. Sodium phenylacetate and sodium benzoate prescribing information. Mechanism of action.Official mechanism source for the benzoate–glycine–hippurate pathway. The labelled product is a phenylacetate/benzoate combination, not PB or benzoate alone. ↩
3. PubChem / MetaCyc. Urea cycle. Pathway PWY-4984.Curated biochemical pathway: ammonia and aspartate nitrogen enter urea; ornithine is recycled. ↩
4. Davies et al.. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology, 2009.Animal liver-disease experiment. The acute four-arm comparison administered phenylbutyrate and native L-ornithine; no cancer efficacy was tested. ↩
5. Nagamani et al.. A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers. Genetics in Medicine, 2018.Seven-person crossover study: drug-conjugated nitrogen, pharmacokinetics and study-era costs; not a cancer trial. ↩
6. Bell et al.. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metabolism, 2023.Cancer mouse experiments with supporting human observations. GPB was tested separately; the checkpoint combination used ornithine. ↩
7. Chen et al.. 4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α. Clinical and Translational Medicine, 2021.Cell and mouse findings with timing-dependent tumour promotion; not evidence of universal PB harm. ↩
8. Tong et al.. Cancer proteome and metabolite changes linked to SHMT2. PLOS ONE, 2020.Cell and immunodeficient-mouse study: benzoate changed glycine metabolism without significantly reducing xenograft growth. ↩
9. Kundu et al.. Sodium benzoate, a food additive and a metabolite of cinnamon, enriches regulatory T cells via STAT6-mediated upregulation of TGFβ. Journal of Immunology, 2016.Immune-cell and autoimmune-mouse experiments; relevance to cancer combinations is a hypothesis. ↩
10. Tharp et al.. Tumour-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nature Cancer, 2024.Breast-cancer mouse and functional immune experiments, including an ornithine/anti-PD-1 counterexample. ↩
11. Yilmaz and Karabay. Food additive sodium benzoate (NaB) activates NFκB and induces apoptosis in HCT116 cells. Molecules, 2018.High-concentration cell-culture findings; not evidence of clinical anticancer efficacy. ↩